Chronological view of peak and diphasic dyskinesia, wearing off and freezing in Parkinson’s disease: 1212 Korean population
Objective: To evaluate the gross chronological trend of 4 motor complications - peak dose dyskinesia, diphasic dyskinesia, wearing off and freezing. Background: Dyskinesia, wearing off…Differences in the Unified Dyskinesia Rating Scale based on age, Parkinson´s Disease and Dyskinesias duration
Objective: To analyze the Unified Dyskinesia Rating Scale (UDysRS) scores on Historical, Objective parts and their differences based on age, Parkinson´s disease (PD) and dyskinesias…Clinical practice of levodopa in parkinsonism
Objective: This study is for the clinical effect of levodopa in parkinsonism. Background: Levodopa was common used in Parkinson disease. Levodopa induced dyskinesia(LID) is the…Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)
Objective: To evaluate whether levodopa induced dyskinesia is preventable in the treatment of patients with Parkinson’s disease. Background: Dyskinesia is one of the major complications…Retrospective study on a cohort of 285 PD patients: Does the side of onset influence the global clinical phenotype?
Objective: To describe demographic and clinical characteristics of a cohort of 285 consecutive PD patients and to understand the phenotypic differences of right onset (RPD)…Lycopene ameliorates haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation
Objective: The study was undertakento investigate the role of striatal neurotransmitters and neuroinflammatory cytokines in the neuroprotective effect of lycopene against haloperidol induced orofacial dyskinesia…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings
Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…Regulation of aberrant striatal oscillations by glutamate receptor blockade in parkinsonian non-human primates
Objective: To study the abnormal striatal oscillations and regulation of striatal oscillatory activities by micro-infusion of glutamate receptor antagonist in the non-human primate model of…Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity
Objective: To investigate the mechanism(s) of action of xenon inhalation for the treatment of L-DOPA-induced dyskinesia. Background: L-dopa-induced dyskinesia (LID) is one of the most…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 44
- Next Page »